NCT06900218View on ClinicalTrials.gov

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

664

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2030

Study Completion Date

May 1, 2033

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG

Sintilimab

Sintilimab 200 mg, administered on Day 1, every 3 weeks for a total of 9 cycles

DRUG

Capecitabine

Capecitabine 650 mg/m², taken orally twice daily, continuously from Day 1 to Day 21, every 3 weeks, for a maximum of 1 year.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT06900218 - PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter